Aoyama Y - Search Results

1

Relationship between central corneal thickness and visual field defect in open-angle glaucoma.

Lin W, Aoyama Y, Kawase K, Yamamoto T. Lin W, et al. Among authors: aoyama y. Jpn J Ophthalmol. 2009 Sep;53(5):477-81. doi: 10.1007/s10384-009-0702-7. Epub 2009 Oct 22. Jpn J Ophthalmol. 2009. PMID: 19847601

2

[Effect of various anti-glaucoma eyedrops on human corneal epithelial cells].

Aoyama Y, Motoki M, Hashimoto M. Aoyama Y, et al. Nippon Ganka Gakkai Zasshi. 2004 Feb;108(2):75-83. Nippon Ganka Gakkai Zasshi. 2004. PMID: 15022429 Japanese.

3

Effects of timolol-related ophthalmic solutions on cultured human conjunctival cells.

Kawase K, Lin W, Aoyama Y, Yamamoto T, Shimazawa M, Hara H. Kawase K, et al. Among authors: aoyama y. Jpn J Ophthalmol. 2010 Nov;54(6):615-21. doi: 10.1007/s10384-010-0881-2. Epub 2010 Dec 30. Jpn J Ophthalmol. 2010. PMID: 21191725

4

Macular retinal thickness in glaucoma with superior or inferior visual hemifield defects.

Inuzuka H, Kawase K, Sawada A, Aoyama Y, Yamamoto T. Inuzuka H, et al. Among authors: aoyama y. J Glaucoma. 2013 Jan;22(1):60-4. doi: 10.1097/IJG.0b013e318225472a. J Glaucoma. 2013. PMID: 21878820

5

Effects of dorzolamide hydrochloride on ocular tissues.

Inoue J, Oka M, Aoyama Y, Kobayashi S, Ueno S, Hada N, Takeda T, Takehana M. Inoue J, et al. Among authors: aoyama y. J Ocul Pharmacol Ther. 2004 Feb;20(1):1-13. doi: 10.1089/108076804772745419. J Ocul Pharmacol Ther. 2004. PMID: 15006154

6

Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors.

Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y, Saito T, Masuda N, Watanabe H, Taguchi T, Kakihara T, Aoyama Y, Hashimoto Y, Nakagawa K. Satoh T, et al. Among authors: aoyama y. Clin Cancer Res. 2009 Jun 1;15(11):3872-80. doi: 10.1158/1078-0432.CCR-08-1946. Epub 2009 May 26. Clin Cancer Res. 2009. PMID: 19470738 Clinical Trial.

7

Lack of differences in the pharmacokinetics of sepantronium bromide (YM155) between US and Japanese patients with advanced solid tumors or non-Hodgkin lymphoma.

Aoyama Y, Katashima M, Sawamoto T. Aoyama Y, et al. Biopharm Drug Dispos. 2013 Mar;34(2):137-40. doi: 10.1002/bdd.1827. Epub 2012 Dec 28. Biopharm Drug Dispos. 2013. PMID: 23138529 Clinical Trial.

8

Population pharmacokinetic modeling of sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma.

Aoyama Y, Kaibara A, Takada A, Nishimura T, Katashima M, Sawamoto T. Aoyama Y, et al. Invest New Drugs. 2013 Apr;31(2):443-51. doi: 10.1007/s10637-012-9867-x. Epub 2012 Aug 16. Invest New Drugs. 2013. PMID: 22892872 Free PMC article. Clinical Trial.

9

Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment.

Aoyama Y, Nishimura T, Sawamoto T, Satoh T, Katashima M, Nakagawa K. Aoyama Y, et al. Cancer Chemother Pharmacol. 2012 Sep;70(3):373-80. doi: 10.1007/s00280-012-1913-z. Epub 2012 Jul 18. Cancer Chemother Pharmacol. 2012. PMID: 22806304 Free PMC article.

10

Medical Writing Competency Model - Section 1: Functions, Tasks, and Activities.

Clemow DB, Wagner B, Marshallsay C, Benau D, L'Heureux D, Brown DH, Dasgupta DG, Girten E, Hubbard F, Gawrylewski HM, Ebina H, Stoltenborg J, York JP, Green K, Wood LF, Toth L, Mihm M, Katz NR, Vasconcelos NM, Sakiyama N, Whitsell R, Gopalakrishnan S, Bairnsfather S, Wanderer T, Schindler TM, Mikyas Y, Aoyama Y. Clemow DB, et al. Among authors: aoyama y. Ther Innov Regul Sci. 2018 Jan;52(1):70-77. doi: 10.1177/2168479017721585. Epub 2017 Sep 1. Ther Innov Regul Sci. 2018. PMID: 29714611

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results